Table 4.
Ratios of erythrocyte fatty acid concentrations among veterans and risk of all prostate cancer, Gleason =6 prostate cancer and Gleason >= 7 prostate cancer as compared to PSA normal controls*. (Odds Ratio (OR) and 95% Confidence Interval (95% CI).
| Tertiles of Erythrocyte FA levels | 1 | 2 | 3 | P value trend |
|---|---|---|---|---|
| n-7 Saturation Index (16:0/16:1 n7) | 0 < n ≤ 53.18 | 53.18 < n ≤79.22 | 79.22 < n | |
| All Cancer Vs. Control | 1.00 | 1.38 (0.77-2.49) | 0.99 (0.54-1.81) | 0.77 |
| Gleason =6 Vs. Control | 1.36 (0.65-2.83) | 0.89 (0.41-1.93) | 0.95 | |
| Gleason >=7 Vs. Control | 1.61 (0.73-3.54) | 1.25 (0.56-2.76) | 0.48 | |
| n-9 Saturation Index (18:0/18:1 n9) | 0 < n ≤ 1.12 | 1.12 < n ≤1.23 | 1.23 < n | |
| All Cancer Vs. Control | 1.00 | 1.67 (0.60-2.28) | 1.41 (0.78-2.55) | 0.20 |
| Gleason =6 Vs. Control | 1.14 (0.51-2.71) | 2.33 (1.10-4.93) | 0.02 | |
| Gleason >=7 Vs. Control | 0.86 (0.40-1.86) | 0.90 (0.44-1.87) | 0.92 | |
| Palmitic : Stearic (16:0/18:0) | 0 < n ≤ 1.28 | 1.28 < n ≤ 1.40 | 1.40 < n | |
| All Cancer Vs. Control | 1.00 | 1.41 (0.80-2.49) | 0.87 (0.47-1.61) | 0.65 |
| Gleason =6 Vs. Control | 1.01 (0.49-2.08) | 0.81 (0.38-1.74) | 0.58 | |
| Gleason >=7 Vs. Control | 1.95 (0.92-4.15) | 0.92 (0.40-2.15) | 0.81 | |
| Total n-31 : Total n-62 | 0 < n≤ 0.18 | 0.18 ≤ 0.22 | 0.22 < n | |
| All Cancer Vs. Control | 1.00 | 0.98 (0.54-1.78) | 1.22 (0.66-2.25) | 0.38 |
| Gleason =6 Vs. Control | 1.17 (0.54-2.55) | 1.43 (0.64-3.21) | 0.26 | |
| Gleason >=7 Vs. Control | 0.75 (0.34-1.64) | 1.01 (0.46-2.20) | 0.78 | |
| ALA:EPA (18:3n3/ 20:5n3) | 0 < n ≤0.25 | 0.25 < n ≤ 0.35 | 0.35 < n | |
| All Cancer Vs. Control | 1.00 | 0.54 (0.30-0.97) | 0.62 (0.35-1.12) | 0.05 |
| Gleason =6 Vs. Control | 0.38 (0.17-0.82) | 0.53 (0.25-1.11) | 0.03 | |
| Gleason >=7 Vs. Control | 0.57 (0.26-1.26) | 0.83 (0.39-1.77) | 0.41 | |
| EPA+DHA:AA ((20:5n-3 + 22:6n-3)/ 20:4n-6) | 0 < n ≤0.15 | 0.15 < n ≤ 0.18 | 0.18 < n | |
| All Cancer Vs. Control | 1.00 | 0.92 (0.50-1.68) | 1.07 (0.58-1.97) | 0.83 |
| Gleason =6 Vs. Control | 1.48 (0.66-3.34) | 1.54 (0.67-3.53) | 0.23 | |
| Gleason >=7 Vs. Control | 0.54 (0.24-1.22) | 0.78 (0.36-1.70) | 0.45 | |
| LA:GLA (18:2/18:3n-6) | 0 < n ≤6.17 | 6.17 < n ≤ 7.61 | 7.61< n | |
| All Cancer Vs. Control | 1.00 | 1.02 (0.56-1.84) | 0.96 (0.54-1.70) | 0.99 |
| Gleason =6 Vs. Control | 0.77 (0.37-1.63) | 0.76 (0.37-1.53) | 0.46 | |
| Gleason >=7 Vs. Control | 1.93 (0.85-4.36) | 1.74 (0.79-3.85) | 0.23 | |
| dGLA:AA (20:3n6/ 20:4n6) | 0 < n ≤0.09 | 0.09 < n ≤ 0.11 | 0.11 < n | |
| All Cancer Vs. Control | 1.00 | 1.20 (0.67-2.12) | 1.28 (0.71-2.31) | 0.99 |
| Gleason =6 Vs. Control | 1.33 (0.63-2.81) | 1.30 (0.61-2.80) | 0.43 | |
| Gleason >=7 Vs. Control | 1.10 (0.53-2.30) | 0.99 (0.46-2.14) | 0.97 |
*
126 Prostate cancer, 61 Gleason =6, 63 Gleason >=7, 182 clinic controls. Models adjusted for age, BMI, race, and family history of prostate cancer.
1
18:3n-3 + 20:3n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3
2
18:2n-6cc + 18:3n-6 + 20:2n-6 + 20:3n-6 + 20:4n-6 + 22:2n-6 + 22:4n-6